These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27557937)

  • 21. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
    Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron absorption and bioavailability in rats of micronized dispersible ferric pyrophosphate.
    Sakaguchi N; Rao TP; Nakata K; Nanbu H; Juneja LR
    Int J Vitam Nutr Res; 2004 Jan; 74(1):3-9. PubMed ID: 15060895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients.
    Landry R; Jacobs PM; Davis R; Shenouda M; Bolton WK
    Am J Nephrol; 2005; 25(4):400-10. PubMed ID: 16088081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC-0974, an Anti-Hemojuvelin Antibody, in Healthy Participants.
    Novikov N; Buch A; Yang H; Andruk M; Liu G; Wu M; Howell H; MacDonald B; Savage W
    J Clin Pharmacol; 2024 Aug; 64(8):953-962. PubMed ID: 38515275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary experience on the use of sucrosomial iron in hemodialysis: focus on safety, hemoglobin maintenance and oxidative stress.
    Reggiani F; Colombo G; Astori E; Landoni L; Finazzi S; Milzani A; Angelini C; Dalle-Donne I; Cucchiari D
    Int Urol Nephrol; 2022 May; 54(5):1145-1153. PubMed ID: 34510284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial.
    Macher S; Drexler C; Lindenau I; Sareban N; Schlenke P; Amrein K
    Trials; 2016 Oct; 17(1):527. PubMed ID: 27793204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron absorption from meat pate fortified with ferric pyrophosphate in iron-deficient women.
    Navas-Carretero S; Pérez-Granados AM; Sarriá B; Vaquero MP
    Nutrition; 2009 Jan; 25(1):20-4. PubMed ID: 18752926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron Absorption from Bouillon Fortified with Iron-Enriched Aspergillus oryzae Is Higher Than That Fortified with Ferric Pyrophosphate in Young Women.
    Bries AE; Hurrell RF; Reddy MB
    J Nutr; 2020 May; 150(5):1109-1115. PubMed ID: 32073619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
    Modi NB; Shames R; Lickliter JD; Gupta S
    Eur J Haematol; 2024 Sep; 113(3):340-350. PubMed ID: 38785334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
    Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
    Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physicochemical characterization of ferric pyrophosphate citrate.
    Gupta A; Pratt R; Mishra B
    Biometals; 2018 Dec; 31(6):1091-1099. PubMed ID: 30324285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.
    Seligman PA; Dahl NV; Strobos J; Kimko HC; Schleicher RB; Jones M; Ducharme MP
    Pharmacotherapy; 2004 May; 24(5):574-83. PubMed ID: 15162891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
    Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
    Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
    J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.